Elsevier MDL launches MDL® Registration built on the MDL® Isentris® system

San Ramon, CA, August 1, 2006 – Elsevier MDL has launched the MDL® Registration application to assist life sciences research organizations with building and managing one of their most valuable assets, the corporate compound registry. As the market leader in compound registration, chemical representation and manipulation and molecule and reaction storage and searching technology, Elsevier MDL has developed a system that embodies best registration practices for organizations of all sizes.

Corporate compound registry systems are the lifeblood of life science research organizations. They uniquely identify each substance and each batch of a substance, whether synthesized or procured, and enable organizations to unambiguously associate physical and biological properties, for example from biological screening, with each specific instance of the substance.

MDL Registration is built on the MDL® Isentris® system and provides out-of-the-box functionality for building high-quality compound registries. MDL Isentris is a new-generation, open-technology, n-tier informatics system for integrating data, workflow applications and business processes.

MDL Registration also provides the foundation for custom registration projects integrating with existing applications such as an electronic laboratory notebook (ELN). Similarly, it can be used to consolidate the separate registries of merged organizations or to migrate an existing registration system to the Isentris system. The flexible registration system is extensively customizable at the user interface, middle tier domain services, business rules and database levels, enabling organizations of any size to readily integrate it within their existing business processes.

“MDL Registration leverages Elsevier MDL’s industry-leading expertise in the representation and searching of chemical structures, providing research organizations with a flexible, configurable tool for registering substance, chemical structure and batch information in a central database,” said Dr. Trevor Heritage, senior vice president and chief scientific officer at Elsevier MDL. “The underlying Isentris technology enables scientists to browse chemical and biological data in a single view, making it easier for researchers to assess the outcome of an experiment or prioritize new compounds for future testing.”

MDL Registration automatically verifies drawing conventions, normalizes structure data in accordance with corporate representation rules and checks for uniqueness before assigning corporate IDs and storing submitted substances in the database. The system supports the integration of custom calculators to determine additional properties. As an Isentris product, MDL Registration is tightly integrated with both MDL® Assay Explorer® and MDL® Plate Manager (for handling biological data and test samples) and with MDL® Notebook (an electronic notebook for managing laboratory workflows and data entry in an e-R&D environment).

For more information about building and managing corporate compound registries with MDL Registration, visit www.mdl.com.

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. 

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com. About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contacts:
Jean Holt
Senior Director, Marketing and Communications
Elsevier MDL
Phone: (925) 543-7398
j.holt@mdl.com